By VFuture Media Tech & Biotech Desk June 10, 2026
In a major strategic move underscoring its push into precision medicine and life sciences, Samsung Electronics has invested $175 million in an upsized Series E funding round for Element Biosciences, a San Diego-based genomics innovator. The investment makes Samsung the largest shareholder in the privately held company and deepens a longstanding partnership aimed at advancing next-generation sequencing, multiomics, and AI-powered diagnostics.
Strategic Investment in Genomics Leadership
Element Biosciences, founded in 2017, specializes in democratizing access to high-quality, affordable biological tools. Its flagship AVITI™ benchtop sequencing system, launched in 2022, uses a novel Avidity Sequencing (sequencing-by-binding) chemistry that delivers superior accuracy and lower costs compared to traditional methods. The company has since expanded into a broader ecosystem of genomic, transcriptomic, protein, spatial, and cellular analysis tools.
The new capital will accelerate commercialization efforts, including:
- Expansion of the AVITI platform and the recently announced high-throughput VITARI™ system.
- Upcoming launches of AVITI Dx™ (for diagnostic applications) and tissue profiling capabilities on AVITI24™.
- Global market expansion across more than 40 countries.
- Development of an open, interoperable architecture for partners in research, pharma, and clinical settings.
Element’s technology supports applications from foundational research and drug development to personalized medicine and early disease detection.
Samsung’s Vision for Synergies
Samsung described the deal as a step to combine Element’s sequencing and multiomics expertise with its own strengths in AI, medical devices, and digital health technologies.
TM Roh, President and Head of the Device eXperience (DX) Division at Samsung Electronics, stated:
“Element has made remarkable progress since our prior investment. Alongside their advancement in next-generation sequencing, they have made foundational innovations in multiomics and clinical workflows that will play a crucial role in the further development of groundbreaking research and clinical applications in precision medicine and personalized diagnostics.”
Samsung views sequencing as a foundational pillar for precision medicine and plans to pursue new opportunities in genetic diagnostics and beyond. The investment builds on Samsung’s earlier participation in Element’s 2024 Series D round.
Market Context and Implications
The gene-sequencing market remains competitive, with Illumina as the dominant player. Element positions itself as a disruptive alternative emphasizing cost-efficiency, data quality, and flexibility—key factors as labs and clinics demand more accessible tools for large-scale genomic analysis.
The funding round size beyond Samsung’s contribution was not disclosed, nor was the post-money valuation. The transaction is subject to regulatory approval, likely including CFIUS review given the sensitive nature of genetic data and foreign investment.
Molly He, CEO and co-founder of Element Biosciences, welcomed the support:
“This financing represents a powerful vote of confidence in our vision, our technology, and our team’s ability to execute… This investment enables us to continue delivering transformative technologies that empower scientific discovery and improve human health.”
The Bigger Picture
Samsung’s move aligns with its broader strategy to expand beyond consumer electronics and semiconductors into high-growth areas like biotech, medtech, and AI-driven healthcare. As genomics data explodes and AI tools mature for biological insights, partnerships like this could accelerate the development of affordable, scalable precision medicine solutions.
Element Biosciences continues to gain traction, recently earning recognition on Fast Company’s list of the World’s Most Innovative Companies. With this fresh capital and Samsung’s backing, the company is well-positioned to challenge incumbents and expand its footprint in research, translational science, and clinical applications.
VFuture Media will monitor the closing of the round, product launches, and emerging synergies between the two companies.
Leave a Comment